logo

For the Inventor, By the Inventor

Osaka, Japan

Sumitomo Pharma Co., Ltd.


USPTO Granted Patents = 66



Trademarks = 29

Forward Citations = 24

Loading Chart...
Loading Chart...

143 inventors (with patents filed for the assignee):

goldMedal Hitoshi Ban (17 out of 41 patents)

silverMedal Seiji Kamioka (7 out of 18 patents)

bronzeMedal Masayo Takahashi (6 out of 19 patents)

4.  Yoshiaki Isobe (6 out of 30 patents)

5.  Hitoshi Watanabe (6 out of 11 patents)

6.  Yohei Ikuma (5 out of 12 patents)

7.  Naoaki Shimada (4 out of 29 patents)

8.  Wataru Hirose (4 out of 10 patents)

9.  Suguru Yamasaki (4 out of 8 patents)

10.  Yoshiki Sasai (4 out of 37 patents)

11.  Hidefumi Yoshinaga (4 out of 19 patents)

12.  Hidenori Kimura (4 out of 11 patents)

13.  Jeremy Besnard (4 out of 9 patents)

14.  Yosuke Takanashi (4 out of 10 patents)

15.  Takao Kuroda (4 out of 30 patents)


Core Competencies:
Vaccine Adjuvants
Retinal Tissue
Therapeutic Drugs
Influenza Vaccine
WT1 Peptides
Dihydrochromene Derivatives
Antibody-Drug Conjugates
Serotonin Receptor Activity
Cell Progenitor Methods
Oxadiazole Derivatives
Heterocyclic Compounds
Biotherapeutics

66 patents:

1. 12503463 - Aliphatic acid amide derivative (2025-12-23),
2. 12491240 - METHOD FOR PRODUCING INFLUENZA HA SPLIT VACCINE (2025-12-09),
3. 12440560 - Substituted pyrimidines as vaccine adjuvants (2025-10-14),
4. 12427192 - Water soluble adjuvant and composition containing same (2025-09-30),
5. 12410154 - 5-heteroaryl-1H-pyrazol-3-amine derivative (2025-09-09),
6. 12404268 - 2-heteroaryl aminoquinazolinone derivative (2025-09-02),
7. 12398149 - Dihydrochromene derivatives (2025-08-26),
8. 12398125 - Nitrogen-containing saturated heterocyclyl derivative (2025-08-26),
9. 12385008 - Method for producing retinal tissue (2025-08-12),
10. 12383608 - WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides (2025-08-12),
11. 12312419 - Hemiasterlin derivative having cysteine residue (2025-05-27),
12. 12304889 - Method for producing cis-(-)-flocino piperidol (2025-05-20),
13. 12291720 - Production method for retinal tissue (2025-05-06),
14. 12285543 - Human cell population comprising human retinal progenitor cells without an ISL1 gene for transplantation and methods of use thereof (2025-04-29),
15. 12263167 - Optically active azabicyclo ring derivative (2025-04-01),
Company Overview
Sumitomo Pharma Co., Ltd., headquartered in Osaka, Japan, is a prominent player in the field of vaccine development. The company specializes in creating innovative therapeutic solutions, focusing on vaccine adjuvants and influenza vaccines. Its research extends to retinal tissue therapies and the development of antibody-drug conjugates. Additionally, Sumitomo Pharma explores advanced compounds such as dihydrochromene derivatives and WT1 peptides, contributing significantly to the advancement of medical science and public health.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

66 Patents

#155 in Osaka

#1,458 in Japan

#11,167 in the World

Osaka, JP
Osaka, Japan

Sumitomo Pharma Co., Ltd.

Forward Citations = 24

143 inventors:

goldMedal Hitoshi Ban (17 out of 41 patents)

silverMedal Seiji Kamioka (7 out of 18 patents)

bronzeMedal Masayo Takahashi (6 out of 19 patents)

4.  Yoshiaki Isobe (6 out of 30 patents)

5.  Hitoshi Watanabe (6 out of 11 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Sumitomo Pharma Co., Ltd.. Retrieved from https://idiyas.com/company/sumitomo-pharma-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…